Greedy Insider
RNA Insider Trades and Greediness Scores
Atrium Therapeutics, Inc. (RNA) insider trades: since Sep 18, 2026, Greedy Insider recorded 0 open-market buys and 8 sales on Form 4 from 8 insiders. The strongest recent filing scored 83 (Strong).
Who bought and who sold
Across the last 8 scoreable Form 4 transactions in RNA, 0 were open-market purchases and 8 were sales. The table lists the most recent filings with each one's Greediness Score, so the structurally unusual trades are easy to spot first.
| Insider | Role | Type | Shares | Date | Score | ||
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | See Remarks | Sell | 11632.0 | 104106.4 | 2026-09-18 | 71 | View |
| Younis Husam | Chief Scientific Officer | Sell | 11216.0 | 100383.2 | 2026-09-18 | 83 | View |
| Hughes Steven George | Chief Medical Officer | Sell | 21459.0 | 192058.05 | 2026-09-18 | 83 | View |
| Kenney Stephanie | See Remarks | Sell | 2375.0 | 21256.25 | 2026-09-18 | 71 | View |
| Flanagan W. Michael | Director | Sell | 22812.0 | 204167.4 | 2026-09-18 | 78 | View |
| Boyce Sarah | Director | Sell | 126418.0 | 1131441.1 | 2026-09-18 | 78 | View |
| Winslow Brendan R. | CFO | Sell | 6742.0 | 60340.9 | 2026-09-18 | 83 | View |
| Hoyos Rocio Martin | Chief Strategy Officer | Sell | 8320.0 | 74464.0 | 2026-09-18 | 83 | View |
The strongest recent filing
Younis Husam (Chief Scientific Officer) sold 11,216 shares of Atrium Therapeutics, Inc. on Sep 18, 2026, a filing that scored 83 (Strong). It scored Strong because a senior insider was trading and several insiders moved the same way within a week. The score describes the filing, not future returns. This is not investment advice.
Cluster activity
A cluster buy is present: 8 insiders (Gallagher Kathleen P., Younis Husam, Hughes Steven George, Kenney Stephanie) traded RNA the same direction within a 7-day window. Shared conviction is a stronger structural signal than a lone trade.
How this compares with Atrium Therapeutics, Inc.'s own history
Open-market buys make up 0% of the 8 scoreable RNA transactions on record between Sep 18, 2026 and Sep 18, 2026. Comparing a filing with the company's own buy/sell mix is how you tell a routine disposal from an unusual accumulation.
Methodology and sources
Scores come from six published, user-adjustable factors (insider role, cluster activity, trade size versus the insider's own history, position impact, filing urgency, and direct versus indirect ownership). The score describes the filing, not future returns. This is not investment advice.
Key facts
- Scoreable Form 4 transactions on record: 8
- Open-market buys: 0
- Sales: 8
- Distinct insiders: 8
- Strongest recent Greediness Score: 83 (Strong)
Primary sources
Related
- Strongest filing
- RNA in the live feed
- How the Greediness Score works
- What is a cluster buy?
- Form 4 transaction codes
The score describes the filing, not future returns. This is not investment advice.